Ironwood Pharmaceuticals (IRWD) Long-Term Deferred Tax (2021 - 2026)

Ironwood Pharmaceuticals (IRWD) has 6 years of Long-Term Deferred Tax data on file, last reported at $84.2 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax fell 41.32% year-over-year to $84.2 million; the trailing twelve-month figure through Mar 2026 stood at $84.2 million (down 41.32% YoY), and the FY2025 full-year result was $103.4 million, down 28.29% from the prior year.
• Long-Term Deferred Tax slipped to $84.2 million in Q1 2026, from $103.4 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $335.4 million in Q1 2022 to a low of $84.2 million in Q1 2026.
• A 5-year average of $206.9 million and a median of $206.3 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax slipped 5.11% in 2022 and sank 45.13% in 2025, its largest moves.
• Tracing IRWD's Long-Term Deferred Tax over 5 years: stood at $283.7 million in 2022, then slipped by 25.15% to $212.3 million in 2023, then plunged by 32.07% to $144.2 million in 2024, then slipped by 28.29% to $103.4 million in 2025, then dropped by 18.56% to $84.2 million in 2026.
• Business Quant data shows IRWD's Long-Term Deferred Tax at $84.2 million in Q1 2026, $103.4 million in Q4 2025, and $101.7 million in Q3 2025.